Processa Pharmaceuticals, Inc.
Sector: Pharmaceutical PreparationsIndustry: BiotechnologyCountry: USExchange: Nasdaq
DilutionScan read 54 of Processa Pharmaceuticals, Inc.'s SEC filings and found 10 warrant series, 2 convertibles, 1 ATM program, 2 shelf registrations, 2 S-1 registrations and 5 completed offerings on file for PCSA. The latest dilution event on file is a registration statement on Oct 23, 2026. Analysis updated Oct 29, 2026.
Signal8 Summary
PCSA
Distressed biotech with exhausted cash
Snapshot
Processa is a clinical-stage biotech with zero revenue and severe financial strain. It burned $11.4M in free cash flow against only $5.5M in cash, resulting in a negative cash runway. The company recently executed a 1-for-25 reverse split and massively diluted shareholders, increasing the share count by nearly 970% in one year. Despite this, nine insiders, including the CEO and CFO, have collectively purchased about $163K of stock in the last 90 days, a significant bet for a company of this size.
Ownership
Institutions hold 4.7% and insiders hold 3.1%.
